See also this year's filing and all EDGAR filings for this company.
PDF Report 0001328143_2020_Adamas_Pharmaceuticals_Inc.pdf
Logs
| warning | Missing logo | subcommand.report | {} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001328143')"} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001328143, Adamas Pharmaceuticals Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 150,320,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 2,449,000 |
| 3 | remainder_Assets | 9,389,000 |
| 4 | LiabilitiesCurrent | 26,948,000 |
| 5 | LiabilitiesNoncurrent | 136,103,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 2,469,000 |
| 8 | SellingGeneralAndAdministrativeExpense | 114,369,000 |
| 9 | ResearchAndDevelopmentExpense | 30,034,000 |
| 10 | remainder_Expenses | 12,951,000 |
| 11 | remainder_Revenues | 54,637,000 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | 280,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 162,158,000 |
| 1 | Liabilities | 163,051,000 |
| 2 | Expenses | 159,823,000 |
| 3 | Revenues | 54,637,000 |
| 4 | StockholdersEquity | -893,000 |
| 5 | NetIncome | -105,186,000 |
| 6 | ComprehensiveNetIncome | -105,046,000 |
| 7 | BaseVar | 269,974,500 |
| 8 | EconomicCapitalRatio | -0.655 |
Edgar->Model Mapping
Feature Distribution
Change over Time
